Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

Hepatocellular carcinoma (HCC) accounts for most liver cancers and represents one of the deadliest cancers in the world. Despite the global demand for liver cancer treatments, there remain few options available. The U.S. Food and Drug Administration (FDA) recently approved Lumoxiti, a CD22-targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Bryan D., Ho, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356171/
https://www.ncbi.nlm.nih.gov/pubmed/32575752
http://dx.doi.org/10.3390/biom10060934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356171/
https://www.ncbi.nlm.nih.gov/pubmed/32575752
http://dx.doi.org/10.3390/biom10060934

Ejemplares similares